Multicenter registry studies would allow for expansion of our knowledge on the best pharma- cological and nonpharmacological approaches to treat these arrhythmias. In collaboration with national societies, the National Institutes of Health, and the US Food and Drug Administration, registries could be developed across selected centers to gather important information on safety and long- term outcomes where data are lacking (just as such registries are being developed for AF ablation). Mandatory postmarket surveillance data collection on new drugs for SVT could also be considered by the US Food and Drug Administration as a condition for drug approval. The mechanism and primary etiology of IST remains to be defined advances here would provide a first step on finding better therapies for this disorder. It should be noted that medi- cal advances have resulted in an increase in the number of patients with SVT in specific populations, such as in patients after ablation (especially AF), ACHD patients, and patients of advanced age. As the numbers of these often-complicated patients grow, opportunities arise to perform clinical research to guide future recommendations. New pharmacological therapies are needed, especially for SVT in patients for whom ablation is not an option or has been unsuccessful. Newer drugs that selectively target atrial channels currently under investigation for patients with AF should be investigated for management of AT. Both mapping and ablation techniques need to be further investigated to maximize the likelihood of successful ablation with minimal risk. In the outpatient setting, the added value of new personal monitoring and implantable devices needs to be assessed, and studies of the impact of shared decision making with patients on outcomes are needed for personal monitoring innovations. Finally, we encourage investigation of quality-of-life improve- ment strategies, in addition to cost-effectiveness studies, for the management of SVT. 